亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

榮大醫藥化工有限公司  

阿那曲唑，拉帕替尼，伊班膦酸鈉，氟維司群，恩替卡韋，鹽酸帕洛諾司瓊，索拉菲尼，鹽酸美金剛胺，鹽酸米那普倫，利托那韋中間體，胡椒酸，伊馬替尼，來曲唑，磷酸奧司他韋等

搜索
網站公告
阿那曲唑，拉帕替尼，伊班膦酸鈉，氟維司群，恩替卡韋，鹽酸帕洛諾司瓊，索拉菲尼，鹽酸美金剛胺，鹽酸米那普倫，利托那韋中間體，胡椒酸，伊馬替尼，來曲唑，磷酸奧司他韋等
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人：黎女士
  • 電話：0571-28182190
  • 郵件：shelly@rdpharm.com
  • 傳真：0571-28281887
  • QQ：1833436340
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 231278-20-9 拉帕替尼中間體-1
231278-20-9 拉帕替尼中間體-1
單價 面議對比
詢價 暫無
發貨 浙江湖州市付款后3天內
型號 231278-20-9
過期 長期有效
更新 2014-03-25 13:24
 
詳細信息
 

N-[3-氯-4-(3-氟芐氧基)苯基]-6-碘喹唑啉-4-胺
基本信息
英文名   N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
產品名稱   N-[3-氯-4-(3-氟芐氧基)苯基]-6-碘喹唑啉-4-胺
copyRight
分子結構   CAS 登錄號：231278-20-9, N-[3-氯-4-(3-氟芐氧基)苯基]-6-碘喹唑啉-4-胺
 
分子式   C21H14ClFIN3O
分子量   505.71
CAS 登錄號   231278-20-9
   

©2025 榮大醫藥化工有限公司 版權所有   技術支持：化工網   訪問量:7275  
 
主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |